nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—kidney cancer—melanoma	0.3	1	CtDrD
Sorafenib—RAF1—Vemurafenib—melanoma	0.106	0.42	CbGbCtD
Sorafenib—BRAF—Vemurafenib—melanoma	0.0888	0.352	CbGbCtD
Sorafenib—FLT1—melanoma	0.0697	0.257	CbGaD
Sorafenib—PDGFRA—melanoma	0.0562	0.207	CbGaD
Sorafenib—BRAF—melanoma	0.0514	0.189	CbGaD
Sorafenib—KDR—melanoma	0.0437	0.161	CbGaD
Sorafenib—KIT—melanoma	0.0413	0.152	CbGaD
Sorafenib—ABCG2—Vemurafenib—melanoma	0.0101	0.0399	CbGbCtD
Sorafenib—ABCB1—melanoma	0.00951	0.035	CbGaD
Sorafenib—ABCG2—Dactinomycin—melanoma	0.00669	0.0265	CbGbCtD
Sorafenib—CYP1A2—Carmustine—melanoma	0.00525	0.0208	CbGbCtD
Sorafenib—CYP1A2—Vemurafenib—melanoma	0.00415	0.0164	CbGbCtD
Sorafenib—CYP3A4—Temozolomide—melanoma	0.00397	0.0157	CbGbCtD
Sorafenib—ABCC2—Docetaxel—melanoma	0.00382	0.0151	CbGbCtD
Sorafenib—ABCG2—Docetaxel—melanoma	0.00346	0.0137	CbGbCtD
Sorafenib—CYP2D6—Vemurafenib—melanoma	0.00342	0.0135	CbGbCtD
Sorafenib—CYP1A2—Dacarbazine—melanoma	0.00318	0.0126	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.00255	0.0101	CbGbCtD
Sorafenib—CYP3A7—Docetaxel—melanoma	0.00255	0.0101	CbGbCtD
Sorafenib—ABCB1—Dactinomycin—melanoma	0.00241	0.00955	CbGbCtD
Sorafenib—CYP3A4—Vemurafenib—melanoma	0.00218	0.00861	CbGbCtD
Sorafenib—CYP3A5—Docetaxel—melanoma	0.00191	0.00758	CbGbCtD
Sorafenib—ABCB1—Docetaxel—melanoma	0.00125	0.00493	CbGbCtD
Sorafenib—FLT1—umbilical vein—melanoma	0.000989	0.0328	CbGeAlD
Sorafenib—Regorafenib—EPHA2—melanoma	0.000944	0.326	CrCbGaD
Sorafenib—KDR—umbilical vein—melanoma	0.000836	0.0277	CbGeAlD
Sorafenib—KDR—hindlimb—melanoma	0.000765	0.0254	CbGeAlD
Sorafenib—CYP3A4—Docetaxel—melanoma	0.000747	0.00295	CbGbCtD
Sorafenib—TIE1—endothelium—melanoma	0.000729	0.0242	CbGeAlD
Sorafenib—TIE1—blood vessel—melanoma	0.000673	0.0223	CbGeAlD
Sorafenib—KDR—appendage—melanoma	0.000656	0.0218	CbGeAlD
Sorafenib—FLT4—endothelium—melanoma	0.000603	0.02	CbGeAlD
Sorafenib—FLT4—blood vessel—melanoma	0.000556	0.0184	CbGeAlD
Sorafenib—MKNK2—hair follicle—melanoma	0.000536	0.0178	CbGeAlD
Sorafenib—MKNK1—hair follicle—melanoma	0.00053	0.0176	CbGeAlD
Sorafenib—CDKL2—head—melanoma	0.000489	0.0162	CbGeAlD
Sorafenib—RALBP1—hair follicle—melanoma	0.000484	0.0161	CbGeAlD
Sorafenib—KIT—skin epidermis—melanoma	0.000484	0.016	CbGeAlD
Sorafenib—Regorafenib—FLT1—melanoma	0.000474	0.164	CrCbGaD
Sorafenib—FLT1—endothelium—melanoma	0.000469	0.0155	CbGeAlD
Sorafenib—RAF1—hair follicle—melanoma	0.000458	0.0152	CbGeAlD
Sorafenib—MAPK15—head—melanoma	0.000441	0.0146	CbGeAlD
Sorafenib—FLT1—blood vessel—melanoma	0.000432	0.0143	CbGeAlD
Sorafenib—KDR—endothelium—melanoma	0.000396	0.0131	CbGeAlD
Sorafenib—ZAK—eye—melanoma	0.000391	0.013	CbGeAlD
Sorafenib—Regorafenib—PDGFRA—melanoma	0.000382	0.132	CrCbGaD
Sorafenib—HIPK3—retina—melanoma	0.00038	0.0126	CbGeAlD
Sorafenib—KDR—blood vessel—melanoma	0.000365	0.0121	CbGeAlD
Sorafenib—KIT—endothelium—melanoma	0.000351	0.0116	CbGeAlD
Sorafenib—RET—neck—melanoma	0.000351	0.0116	CbGeAlD
Sorafenib—Regorafenib—BRAF—melanoma	0.000349	0.121	CrCbGaD
Sorafenib—EPHX2—eye—melanoma	0.000328	0.0109	CbGeAlD
Sorafenib—EPHX2—retina—melanoma	0.000325	0.0108	CbGeAlD
Sorafenib—KIT—blood vessel—melanoma	0.000324	0.0107	CbGeAlD
Sorafenib—PDGFRB—blood vessel—melanoma	0.000316	0.0105	CbGeAlD
Sorafenib—ZAK—mammalian vulva—melanoma	0.00031	0.0103	CbGeAlD
Sorafenib—FLT1—neck—melanoma	0.000309	0.0103	CbGeAlD
Sorafenib—RAF1—neck—melanoma	0.000307	0.0102	CbGeAlD
Sorafenib—Regorafenib—KDR—melanoma	0.000297	0.103	CrCbGaD
Sorafenib—FLT4—eye—melanoma	0.000296	0.00981	CbGeAlD
Sorafenib—Regorafenib—KIT—melanoma	0.00028	0.0968	CrCbGaD
Sorafenib—MAP3K7—retina—melanoma	0.000274	0.00908	CbGeAlD
Sorafenib—MKNK2—eye—melanoma	0.000268	0.00888	CbGeAlD
Sorafenib—MKNK2—retina—melanoma	0.000265	0.0088	CbGeAlD
Sorafenib—MKNK1—eye—melanoma	0.000264	0.00877	CbGeAlD
Sorafenib—MKNK1—retina—melanoma	0.000262	0.00869	CbGeAlD
Sorafenib—KDR—neck—melanoma	0.000261	0.00867	CbGeAlD
Sorafenib—MAPK11—head—melanoma	0.000261	0.00866	CbGeAlD
Sorafenib—EPHX2—mammalian vulva—melanoma	0.00026	0.00863	CbGeAlD
Sorafenib—CDK7—head—melanoma	0.000257	0.00852	CbGeAlD
Sorafenib—AURKC—head—melanoma	0.000253	0.00839	CbGeAlD
Sorafenib—RALBP1—eye—melanoma	0.000242	0.00802	CbGeAlD
Sorafenib—RALBP1—retina—melanoma	0.00024	0.00795	CbGeAlD
Sorafenib—EPHA6—head—melanoma	0.000234	0.00777	CbGeAlD
Sorafenib—KIT—neck—melanoma	0.000232	0.00768	CbGeAlD
Sorafenib—FGFR1—mammalian vulva—melanoma	0.000232	0.00768	CbGeAlD
Sorafenib—FLT1—eye—melanoma	0.00023	0.00763	CbGeAlD
Sorafenib—RAF1—eye—melanoma	0.000229	0.00758	CbGeAlD
Sorafenib—FLT1—retina—melanoma	0.000228	0.00756	CbGeAlD
Sorafenib—PDGFRB—neck—melanoma	0.000226	0.0075	CbGeAlD
Sorafenib—ZAK—head—melanoma	0.000222	0.00737	CbGeAlD
Sorafenib—MAP3K7—mammalian vulva—melanoma	0.000219	0.00727	CbGeAlD
Sorafenib—MAP3K19—head—melanoma	0.000213	0.00706	CbGeAlD
Sorafenib—MKNK2—mammalian vulva—melanoma	0.000212	0.00704	CbGeAlD
Sorafenib—MKNK1—mammalian vulva—melanoma	0.00021	0.00696	CbGeAlD
Sorafenib—TIE1—head—melanoma	0.000203	0.00674	CbGeAlD
Sorafenib—RAF1—skin of body—melanoma	0.000199	0.0066	CbGeAlD
Sorafenib—EPHB6—skin of body—melanoma	0.000198	0.00656	CbGeAlD
Sorafenib—KDR—eye—melanoma	0.000194	0.00645	CbGeAlD
Sorafenib—KDR—retina—melanoma	0.000193	0.00639	CbGeAlD
Sorafenib—RALBP1—mammalian vulva—melanoma	0.000192	0.00636	CbGeAlD
Sorafenib—CSF1R—eye—melanoma	0.00019	0.00629	CbGeAlD
Sorafenib—MAPK11—lymph node—melanoma	0.000183	0.00607	CbGeAlD
Sorafenib—FLT1—mammalian vulva—melanoma	0.000182	0.00605	CbGeAlD
Sorafenib—RAF1—mammalian vulva—melanoma	0.000181	0.00602	CbGeAlD
Sorafenib—EPHB6—mammalian vulva—melanoma	0.00018	0.00598	CbGeAlD
Sorafenib—CDK7—lymph node—melanoma	0.00018	0.00597	CbGeAlD
Sorafenib—TAOK2—lymph node—melanoma	0.000179	0.00592	CbGeAlD
Sorafenib—AURKC—lymph node—melanoma	0.000177	0.00588	CbGeAlD
Sorafenib—STK10—mammalian vulva—melanoma	0.000173	0.00573	CbGeAlD
Sorafenib—PDGFRB—eye—melanoma	0.000168	0.00558	CbGeAlD
Sorafenib—FLT4—head—melanoma	0.000168	0.00557	CbGeAlD
Sorafenib—CSF1R—skin of body—melanoma	0.000165	0.00547	CbGeAlD
Sorafenib—ZAK—lymph node—melanoma	0.000156	0.00516	CbGeAlD
Sorafenib—MAP2K5—mammalian vulva—melanoma	0.000154	0.00512	CbGeAlD
Sorafenib—KDR—mammalian vulva—melanoma	0.000154	0.00512	CbGeAlD
Sorafenib—HIPK3—lymph node—melanoma	0.000152	0.00505	CbGeAlD
Sorafenib—MKNK2—head—melanoma	0.000152	0.00504	CbGeAlD
Sorafenib—CSF1R—mammalian vulva—melanoma	0.000151	0.00499	CbGeAlD
Sorafenib—MKNK1—head—melanoma	0.00015	0.00498	CbGeAlD
Sorafenib—KIT—skin of body—melanoma	0.00015	0.00497	CbGeAlD
Sorafenib—RET—head—melanoma	0.000148	0.00492	CbGeAlD
Sorafenib—PDGFRB—skin of body—melanoma	0.000146	0.00485	CbGeAlD
Sorafenib—TIE1—lymph node—melanoma	0.000142	0.00472	CbGeAlD
Sorafenib—RALBP1—head—melanoma	0.000137	0.00455	CbGeAlD
Sorafenib—KIT—mammalian vulva—melanoma	0.000137	0.00453	CbGeAlD
Sorafenib—BRAF—lymph node—melanoma	0.000136	0.00452	CbGeAlD
Sorafenib—PDGFRB—mammalian vulva—melanoma	0.000133	0.00443	CbGeAlD
Sorafenib—FLT1—head—melanoma	0.000131	0.00433	CbGeAlD
Sorafenib—EPHX2—lymph node—melanoma	0.00013	0.00432	CbGeAlD
Sorafenib—RAF1—head—melanoma	0.00013	0.0043	CbGeAlD
Sorafenib—FLT3—lymph node—melanoma	0.000129	0.00429	CbGeAlD
Sorafenib—EPHB6—head—melanoma	0.000129	0.00428	CbGeAlD
Sorafenib—STK10—head—melanoma	0.000124	0.0041	CbGeAlD
Sorafenib—PDGFRA—head—melanoma	0.000122	0.00406	CbGeAlD
Sorafenib—FLT4—lymph node—melanoma	0.000118	0.0039	CbGeAlD
Sorafenib—FGFR1—lymph node—melanoma	0.000116	0.00385	CbGeAlD
Sorafenib—HTR2B—skin of body—melanoma	0.000116	0.00384	CbGeAlD
Sorafenib—MAP2K5—head—melanoma	0.00011	0.00366	CbGeAlD
Sorafenib—KDR—head—melanoma	0.00011	0.00366	CbGeAlD
Sorafenib—MAP3K7—lymph node—melanoma	0.00011	0.00364	CbGeAlD
Sorafenib—CSF1R—head—melanoma	0.000108	0.00357	CbGeAlD
Sorafenib—MKNK2—lymph node—melanoma	0.000106	0.00353	CbGeAlD
Sorafenib—MKNK1—lymph node—melanoma	0.000105	0.00348	CbGeAlD
Sorafenib—RET—lymph node—melanoma	0.000104	0.00344	CbGeAlD
Sorafenib—Gastrointestinal disorder—Vemurafenib—melanoma	0.000103	0.00185	CcSEcCtD
Sorafenib—Fatigue—Vemurafenib—melanoma	0.000103	0.00184	CcSEcCtD
Sorafenib—Neoplasm—Docetaxel—melanoma	0.000103	0.00184	CcSEcCtD
Sorafenib—Haemoglobin—Bleomycin—melanoma	0.000103	0.00183	CcSEcCtD
Sorafenib—Constipation—Vemurafenib—melanoma	0.000102	0.00183	CcSEcCtD
Sorafenib—Haemorrhage—Bleomycin—melanoma	0.000102	0.00182	CcSEcCtD
Sorafenib—Neutropenia—Temozolomide—melanoma	0.000101	0.0018	CcSEcCtD
Sorafenib—Pneumonia—Carmustine—melanoma	9.99e-05	0.00178	CcSEcCtD
Sorafenib—Erectile dysfunction—Temozolomide—melanoma	9.91e-05	0.00177	CcSEcCtD
Sorafenib—KIT—head—melanoma	9.78e-05	0.00324	CbGeAlD
Sorafenib—Renal failure—Carmustine—melanoma	9.76e-05	0.00174	CcSEcCtD
Sorafenib—Weight decreased—Temozolomide—melanoma	9.74e-05	0.00174	CcSEcCtD
Sorafenib—Neuropathy peripheral—Carmustine—melanoma	9.73e-05	0.00174	CcSEcCtD
Sorafenib—Stomatitis—Carmustine—melanoma	9.68e-05	0.00173	CcSEcCtD
Sorafenib—Pneumonia—Temozolomide—melanoma	9.65e-05	0.00172	CcSEcCtD
Sorafenib—RALBP1—lymph node—melanoma	9.61e-05	0.00319	CbGeAlD
Sorafenib—Infestation—Temozolomide—melanoma	9.59e-05	0.00171	CcSEcCtD
Sorafenib—Infestation NOS—Temozolomide—melanoma	9.59e-05	0.00171	CcSEcCtD
Sorafenib—PDGFRB—head—melanoma	9.55e-05	0.00317	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Temozolomide—melanoma	9.51e-05	0.0017	CcSEcCtD
Sorafenib—Flushing—Bleomycin—melanoma	9.48e-05	0.00169	CcSEcCtD
Sorafenib—Body temperature increased—Vemurafenib—melanoma	9.47e-05	0.00169	CcSEcCtD
Sorafenib—Neuropathy peripheral—Temozolomide—melanoma	9.41e-05	0.00168	CcSEcCtD
Sorafenib—Stomatitis—Temozolomide—melanoma	9.35e-05	0.00167	CcSEcCtD
Sorafenib—Hepatic failure—Docetaxel—melanoma	9.21e-05	0.00165	CcSEcCtD
Sorafenib—FLT1—lymph node—melanoma	9.14e-05	0.00303	CbGeAlD
Sorafenib—Cardiac failure congestive—Docetaxel—melanoma	9.13e-05	0.00163	CcSEcCtD
Sorafenib—RAF1—lymph node—melanoma	9.09e-05	0.00301	CbGeAlD
Sorafenib—Hepatobiliary disease—Temozolomide—melanoma	9.07e-05	0.00162	CcSEcCtD
Sorafenib—EPHB6—lymph node—melanoma	9.04e-05	0.003	CbGeAlD
Sorafenib—Alopecia—Bleomycin—melanoma	9.02e-05	0.00161	CcSEcCtD
Sorafenib—Erythema multiforme—Dactinomycin—melanoma	9e-05	0.00161	CcSEcCtD
Sorafenib—Haemoglobin—Carmustine—melanoma	8.96e-05	0.0016	CcSEcCtD
Sorafenib—Haemorrhage—Carmustine—melanoma	8.91e-05	0.00159	CcSEcCtD
Sorafenib—Erythema—Bleomycin—melanoma	8.89e-05	0.00159	CcSEcCtD
Sorafenib—Flushing—Dactinomycin—melanoma	8.84e-05	0.00158	CcSEcCtD
Sorafenib—Hypersensitivity—Vemurafenib—melanoma	8.82e-05	0.00158	CcSEcCtD
Sorafenib—ABCB1—blood vessel—melanoma	8.76e-05	0.00291	CbGeAlD
Sorafenib—Connective tissue disorder—Carmustine—melanoma	8.76e-05	0.00156	CcSEcCtD
Sorafenib—Haemoglobin—Temozolomide—melanoma	8.66e-05	0.00155	CcSEcCtD
Sorafenib—STK10—lymph node—melanoma	8.65e-05	0.00287	CbGeAlD
Sorafenib—Haemorrhage—Temozolomide—melanoma	8.61e-05	0.00154	CcSEcCtD
Sorafenib—Asthenia—Vemurafenib—melanoma	8.59e-05	0.00153	CcSEcCtD
Sorafenib—PDGFRA—lymph node—melanoma	8.57e-05	0.00284	CbGeAlD
Sorafenib—Urinary tract disorder—Temozolomide—melanoma	8.51e-05	0.00152	CcSEcCtD
Sorafenib—Cardiac failure—Docetaxel—melanoma	8.48e-05	0.00152	CcSEcCtD
Sorafenib—Pruritus—Vemurafenib—melanoma	8.47e-05	0.00151	CcSEcCtD
Sorafenib—Connective tissue disorder—Temozolomide—melanoma	8.46e-05	0.00151	CcSEcCtD
Sorafenib—Urethral disorder—Temozolomide—melanoma	8.44e-05	0.00151	CcSEcCtD
Sorafenib—Alopecia—Dactinomycin—melanoma	8.42e-05	0.0015	CcSEcCtD
Sorafenib—Hyponatraemia—Docetaxel—melanoma	8.31e-05	0.00148	CcSEcCtD
Sorafenib—Erythema—Dactinomycin—melanoma	8.29e-05	0.00148	CcSEcCtD
Sorafenib—Pain in extremity—Docetaxel—melanoma	8.28e-05	0.00148	CcSEcCtD
Sorafenib—Flushing—Carmustine—melanoma	8.27e-05	0.00148	CcSEcCtD
Sorafenib—Anaemia—Bleomycin—melanoma	8.22e-05	0.00147	CcSEcCtD
Sorafenib—Diarrhoea—Vemurafenib—melanoma	8.19e-05	0.00146	CcSEcCtD
Sorafenib—Erythema multiforme—Temozolomide—melanoma	8.14e-05	0.00145	CcSEcCtD
Sorafenib—HTR2C—head—melanoma	8.05e-05	0.00267	CbGeAlD
Sorafenib—Tinnitus—Temozolomide—melanoma	8.03e-05	0.00143	CcSEcCtD
Sorafenib—Cardiac disorder—Temozolomide—melanoma	7.99e-05	0.00143	CcSEcCtD
Sorafenib—Flushing—Temozolomide—melanoma	7.99e-05	0.00143	CcSEcCtD
Sorafenib—Arrhythmia—Carmustine—melanoma	7.96e-05	0.00142	CcSEcCtD
Sorafenib—Leukopenia—Bleomycin—melanoma	7.96e-05	0.00142	CcSEcCtD
Sorafenib—Dizziness—Vemurafenib—melanoma	7.92e-05	0.00141	CcSEcCtD
Sorafenib—Alopecia—Carmustine—melanoma	7.88e-05	0.00141	CcSEcCtD
Sorafenib—Angiopathy—Temozolomide—melanoma	7.81e-05	0.0014	CcSEcCtD
Sorafenib—Mental disorder—Carmustine—melanoma	7.81e-05	0.00139	CcSEcCtD
Sorafenib—Immune system disorder—Temozolomide—melanoma	7.78e-05	0.00139	CcSEcCtD
Sorafenib—Mediastinal disorder—Temozolomide—melanoma	7.76e-05	0.00139	CcSEcCtD
Sorafenib—Malnutrition—Carmustine—melanoma	7.76e-05	0.00139	CcSEcCtD
Sorafenib—Erythema—Carmustine—melanoma	7.76e-05	0.00139	CcSEcCtD
Sorafenib—Cough—Bleomycin—melanoma	7.76e-05	0.00139	CcSEcCtD
Sorafenib—MAP2K5—lymph node—melanoma	7.73e-05	0.00256	CbGeAlD
Sorafenib—KDR—lymph node—melanoma	7.73e-05	0.00256	CbGeAlD
Sorafenib—Dehydration—Docetaxel—melanoma	7.7e-05	0.00138	CcSEcCtD
Sorafenib—Anaemia—Dactinomycin—melanoma	7.66e-05	0.00137	CcSEcCtD
Sorafenib—Vomiting—Vemurafenib—melanoma	7.61e-05	0.00136	CcSEcCtD
Sorafenib—Alopecia—Temozolomide—melanoma	7.61e-05	0.00136	CcSEcCtD
Sorafenib—ABCC4—head—melanoma	7.6e-05	0.00252	CbGeAlD
Sorafenib—CYP2B6—skin of body—melanoma	7.59e-05	0.00252	CbGeAlD
Sorafenib—Dry skin—Docetaxel—melanoma	7.59e-05	0.00136	CcSEcCtD
Sorafenib—Myalgia—Bleomycin—melanoma	7.57e-05	0.00135	CcSEcCtD
Sorafenib—HTR2B—head—melanoma	7.56e-05	0.00251	CbGeAlD
Sorafenib—Abdominal pain upper—Docetaxel—melanoma	7.56e-05	0.00135	CcSEcCtD
Sorafenib—Rash—Vemurafenib—melanoma	7.55e-05	0.00135	CcSEcCtD
Sorafenib—Mental disorder—Temozolomide—melanoma	7.55e-05	0.00135	CcSEcCtD
Sorafenib—Dermatitis—Vemurafenib—melanoma	7.54e-05	0.00135	CcSEcCtD
Sorafenib—CSF1R—lymph node—melanoma	7.54e-05	0.0025	CbGeAlD
Sorafenib—ABCG2—mammalian vulva—melanoma	7.5e-05	0.00249	CbGeAlD
Sorafenib—Headache—Vemurafenib—melanoma	7.5e-05	0.00134	CcSEcCtD
Sorafenib—Malnutrition—Temozolomide—melanoma	7.5e-05	0.00134	CcSEcCtD
Sorafenib—Erythema—Temozolomide—melanoma	7.5e-05	0.00134	CcSEcCtD
Sorafenib—Breast disorder—Docetaxel—melanoma	7.48e-05	0.00134	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Docetaxel—melanoma	7.46e-05	0.00133	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Docetaxel—melanoma	7.46e-05	0.00133	CcSEcCtD
Sorafenib—Leukopenia—Dactinomycin—melanoma	7.42e-05	0.00133	CcSEcCtD
Sorafenib—Nasopharyngitis—Docetaxel—melanoma	7.4e-05	0.00132	CcSEcCtD
Sorafenib—Dysgeusia—Temozolomide—melanoma	7.34e-05	0.00131	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Docetaxel—melanoma	7.3e-05	0.0013	CcSEcCtD
Sorafenib—Anaphylactic shock—Bleomycin—melanoma	7.25e-05	0.0013	CcSEcCtD
Sorafenib—Infection—Bleomycin—melanoma	7.21e-05	0.00129	CcSEcCtD
Sorafenib—Anaemia—Carmustine—melanoma	7.17e-05	0.00128	CcSEcCtD
Sorafenib—Dysphagia—Docetaxel—melanoma	7.16e-05	0.00128	CcSEcCtD
Sorafenib—Nausea—Vemurafenib—melanoma	7.11e-05	0.00127	CcSEcCtD
Sorafenib—Thrombocytopenia—Bleomycin—melanoma	7.1e-05	0.00127	CcSEcCtD
Sorafenib—Myalgia—Dactinomycin—melanoma	7.06e-05	0.00126	CcSEcCtD
Sorafenib—Leukopenia—Carmustine—melanoma	6.95e-05	0.00124	CcSEcCtD
Sorafenib—Anaemia—Temozolomide—melanoma	6.93e-05	0.00124	CcSEcCtD
Sorafenib—Anorexia—Bleomycin—melanoma	6.92e-05	0.00124	CcSEcCtD
Sorafenib—Angioedema—Temozolomide—melanoma	6.85e-05	0.00122	CcSEcCtD
Sorafenib—KIT—lymph node—melanoma	6.85e-05	0.00227	CbGeAlD
Sorafenib—Infection—Dactinomycin—melanoma	6.72e-05	0.0012	CcSEcCtD
Sorafenib—Leukopenia—Temozolomide—melanoma	6.71e-05	0.0012	CcSEcCtD
Sorafenib—Hypertension—Carmustine—melanoma	6.7e-05	0.0012	CcSEcCtD
Sorafenib—Neutropenia—Docetaxel—melanoma	6.69e-05	0.0012	CcSEcCtD
Sorafenib—PDGFRB—lymph node—melanoma	6.69e-05	0.00222	CbGeAlD
Sorafenib—Thrombocytopenia—Dactinomycin—melanoma	6.62e-05	0.00118	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Bleomycin—melanoma	6.61e-05	0.00118	CcSEcCtD
Sorafenib—Myalgia—Carmustine—melanoma	6.61e-05	0.00118	CcSEcCtD
Sorafenib—Cough—Temozolomide—melanoma	6.54e-05	0.00117	CcSEcCtD
Sorafenib—Weight decreased—Docetaxel—melanoma	6.47e-05	0.00116	CcSEcCtD
Sorafenib—Hypertension—Temozolomide—melanoma	6.47e-05	0.00116	CcSEcCtD
Sorafenib—Dyspnoea—Bleomycin—melanoma	6.47e-05	0.00116	CcSEcCtD
Sorafenib—Regorafenib—ABCB1—melanoma	6.46e-05	0.0223	CrCbGaD
Sorafenib—Anorexia—Dactinomycin—melanoma	6.45e-05	0.00115	CcSEcCtD
Sorafenib—Pneumonia—Docetaxel—melanoma	6.42e-05	0.00115	CcSEcCtD
Sorafenib—Myalgia—Temozolomide—melanoma	6.38e-05	0.00114	CcSEcCtD
Sorafenib—Arthralgia—Temozolomide—melanoma	6.38e-05	0.00114	CcSEcCtD
Sorafenib—Infestation—Docetaxel—melanoma	6.38e-05	0.00114	CcSEcCtD
Sorafenib—Infestation NOS—Docetaxel—melanoma	6.38e-05	0.00114	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	6.34e-05	0.00113	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Docetaxel—melanoma	6.33e-05	0.00113	CcSEcCtD
Sorafenib—Decreased appetite—Bleomycin—melanoma	6.31e-05	0.00113	CcSEcCtD
Sorafenib—Infection—Carmustine—melanoma	6.29e-05	0.00112	CcSEcCtD
Sorafenib—Acute coronary syndrome—Docetaxel—melanoma	6.29e-05	0.00112	CcSEcCtD
Sorafenib—Renal failure—Docetaxel—melanoma	6.27e-05	0.00112	CcSEcCtD
Sorafenib—Neuropathy peripheral—Docetaxel—melanoma	6.25e-05	0.00112	CcSEcCtD
Sorafenib—Myocardial infarction—Docetaxel—melanoma	6.25e-05	0.00112	CcSEcCtD
Sorafenib—Dry mouth—Temozolomide—melanoma	6.24e-05	0.00112	CcSEcCtD
Sorafenib—Stomatitis—Docetaxel—melanoma	6.22e-05	0.00111	CcSEcCtD
Sorafenib—Jaundice—Docetaxel—melanoma	6.22e-05	0.00111	CcSEcCtD
Sorafenib—Pain—Bleomycin—melanoma	6.2e-05	0.00111	CcSEcCtD
Sorafenib—Thrombocytopenia—Carmustine—melanoma	6.2e-05	0.00111	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Dactinomycin—melanoma	6.16e-05	0.0011	CcSEcCtD
Sorafenib—Anaphylactic shock—Temozolomide—melanoma	6.12e-05	0.00109	CcSEcCtD
Sorafenib—Infection—Temozolomide—melanoma	6.08e-05	0.00109	CcSEcCtD
Sorafenib—Anorexia—Carmustine—melanoma	6.04e-05	0.00108	CcSEcCtD
Sorafenib—Hepatobiliary disease—Docetaxel—melanoma	6.03e-05	0.00108	CcSEcCtD
Sorafenib—Epistaxis—Docetaxel—melanoma	6.02e-05	0.00107	CcSEcCtD
Sorafenib—Nervous system disorder—Temozolomide—melanoma	6e-05	0.00107	CcSEcCtD
Sorafenib—Thrombocytopenia—Temozolomide—melanoma	5.99e-05	0.00107	CcSEcCtD
Sorafenib—Skin disorder—Temozolomide—melanoma	5.94e-05	0.00106	CcSEcCtD
Sorafenib—Decreased appetite—Dactinomycin—melanoma	5.88e-05	0.00105	CcSEcCtD
Sorafenib—Fatigue—Dactinomycin—melanoma	5.83e-05	0.00104	CcSEcCtD
Sorafenib—Anorexia—Temozolomide—melanoma	5.83e-05	0.00104	CcSEcCtD
Sorafenib—Pain—Dactinomycin—melanoma	5.79e-05	0.00103	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Carmustine—melanoma	5.77e-05	0.00103	CcSEcCtD
Sorafenib—Urticaria—Bleomycin—melanoma	5.76e-05	0.00103	CcSEcCtD
Sorafenib—Haemoglobin—Docetaxel—melanoma	5.76e-05	0.00103	CcSEcCtD
Sorafenib—Body temperature increased—Bleomycin—melanoma	5.73e-05	0.00102	CcSEcCtD
Sorafenib—Haemorrhage—Docetaxel—melanoma	5.73e-05	0.00102	CcSEcCtD
Sorafenib—Urinary tract disorder—Docetaxel—melanoma	5.66e-05	0.00101	CcSEcCtD
Sorafenib—Dyspnoea—Carmustine—melanoma	5.65e-05	0.00101	CcSEcCtD
Sorafenib—Connective tissue disorder—Docetaxel—melanoma	5.63e-05	0.00101	CcSEcCtD
Sorafenib—Urethral disorder—Docetaxel—melanoma	5.61e-05	0.001	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Temozolomide—melanoma	5.58e-05	0.000996	CcSEcCtD
Sorafenib—Gastrointestinal pain—Dactinomycin—melanoma	5.53e-05	0.000988	CcSEcCtD
Sorafenib—Decreased appetite—Carmustine—melanoma	5.5e-05	0.000983	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Carmustine—melanoma	5.47e-05	0.000976	CcSEcCtD
Sorafenib—Dyspnoea—Temozolomide—melanoma	5.46e-05	0.000974	CcSEcCtD
Sorafenib—Erythema multiforme—Docetaxel—melanoma	5.42e-05	0.000967	CcSEcCtD
Sorafenib—Pain—Carmustine—melanoma	5.42e-05	0.000967	CcSEcCtD
Sorafenib—Constipation—Carmustine—melanoma	5.42e-05	0.000967	CcSEcCtD
Sorafenib—Dyspepsia—Temozolomide—melanoma	5.39e-05	0.000962	CcSEcCtD
Sorafenib—Vismodegib—ALB—melanoma	5.37e-05	0.0185	CrCbGaD
Sorafenib—Abdominal pain—Dactinomycin—melanoma	5.35e-05	0.000955	CcSEcCtD
Sorafenib—Body temperature increased—Dactinomycin—melanoma	5.35e-05	0.000955	CcSEcCtD
Sorafenib—Hypersensitivity—Bleomycin—melanoma	5.34e-05	0.000955	CcSEcCtD
Sorafenib—ABCC4—lymph node—melanoma	5.33e-05	0.00177	CbGeAlD
Sorafenib—Decreased appetite—Temozolomide—melanoma	5.32e-05	0.00095	CcSEcCtD
Sorafenib—Flushing—Docetaxel—melanoma	5.32e-05	0.00095	CcSEcCtD
Sorafenib—Cardiac disorder—Docetaxel—melanoma	5.32e-05	0.00095	CcSEcCtD
Sorafenib—HTR2B—lymph node—melanoma	5.3e-05	0.00176	CbGeAlD
Sorafenib—Gastrointestinal disorder—Temozolomide—melanoma	5.28e-05	0.000944	CcSEcCtD
Sorafenib—Fatigue—Temozolomide—melanoma	5.28e-05	0.000942	CcSEcCtD
Sorafenib—Pain—Temozolomide—melanoma	5.23e-05	0.000935	CcSEcCtD
Sorafenib—Constipation—Temozolomide—melanoma	5.23e-05	0.000935	CcSEcCtD
Sorafenib—Asthenia—Bleomycin—melanoma	5.2e-05	0.00093	CcSEcCtD
Sorafenib—Angiopathy—Docetaxel—melanoma	5.2e-05	0.000928	CcSEcCtD
Sorafenib—Gastrointestinal pain—Carmustine—melanoma	5.18e-05	0.000925	CcSEcCtD
Sorafenib—Immune system disorder—Docetaxel—melanoma	5.17e-05	0.000924	CcSEcCtD
Sorafenib—Mediastinal disorder—Docetaxel—melanoma	5.16e-05	0.000922	CcSEcCtD
Sorafenib—ABCC2—lymph node—melanoma	5.15e-05	0.00171	CbGeAlD
Sorafenib—Pruritus—Bleomycin—melanoma	5.13e-05	0.000917	CcSEcCtD
Sorafenib—Vismodegib—ABCB1—melanoma	5.12e-05	0.0177	CrCbGaD
Sorafenib—Arrhythmia—Docetaxel—melanoma	5.12e-05	0.000914	CcSEcCtD
Sorafenib—Alopecia—Docetaxel—melanoma	5.06e-05	0.000904	CcSEcCtD
Sorafenib—Mental disorder—Docetaxel—melanoma	5.02e-05	0.000896	CcSEcCtD
Sorafenib—Abdominal pain—Carmustine—melanoma	5.01e-05	0.000894	CcSEcCtD
Sorafenib—Body temperature increased—Carmustine—melanoma	5.01e-05	0.000894	CcSEcCtD
Sorafenib—Gastrointestinal pain—Temozolomide—melanoma	5e-05	0.000894	CcSEcCtD
Sorafenib—Malnutrition—Docetaxel—melanoma	4.99e-05	0.000891	CcSEcCtD
Sorafenib—Erythema—Docetaxel—melanoma	4.99e-05	0.000891	CcSEcCtD
Sorafenib—Hypersensitivity—Dactinomycin—melanoma	4.98e-05	0.00089	CcSEcCtD
Sorafenib—CYP2B6—head—melanoma	4.95e-05	0.00164	CbGeAlD
Sorafenib—Dysgeusia—Docetaxel—melanoma	4.88e-05	0.000872	CcSEcCtD
Sorafenib—Urticaria—Temozolomide—melanoma	4.86e-05	0.000868	CcSEcCtD
Sorafenib—Asthenia—Dactinomycin—melanoma	4.85e-05	0.000867	CcSEcCtD
Sorafenib—Abdominal pain—Temozolomide—melanoma	4.84e-05	0.000864	CcSEcCtD
Sorafenib—Body temperature increased—Temozolomide—melanoma	4.84e-05	0.000864	CcSEcCtD
Sorafenib—Muscle spasms—Docetaxel—melanoma	4.79e-05	0.000856	CcSEcCtD
Sorafenib—Hypersensitivity—Carmustine—melanoma	4.67e-05	0.000833	CcSEcCtD
Sorafenib—Diarrhoea—Dactinomycin—melanoma	4.63e-05	0.000827	CcSEcCtD
Sorafenib—ABCB1—retina—melanoma	4.62e-05	0.00153	CbGeAlD
Sorafenib—Vomiting—Bleomycin—melanoma	4.61e-05	0.000824	CcSEcCtD
Sorafenib—Anaemia—Docetaxel—melanoma	4.61e-05	0.000823	CcSEcCtD
Sorafenib—Rash—Bleomycin—melanoma	4.57e-05	0.000817	CcSEcCtD
Sorafenib—Dermatitis—Bleomycin—melanoma	4.57e-05	0.000816	CcSEcCtD
Sorafenib—Asthenia—Carmustine—melanoma	4.54e-05	0.000811	CcSEcCtD
Sorafenib—Hypersensitivity—Temozolomide—melanoma	4.51e-05	0.000805	CcSEcCtD
Sorafenib—Syncope—Docetaxel—melanoma	4.47e-05	0.000799	CcSEcCtD
Sorafenib—Leukopenia—Docetaxel—melanoma	4.46e-05	0.000797	CcSEcCtD
Sorafenib—Asthenia—Temozolomide—melanoma	4.39e-05	0.000784	CcSEcCtD
Sorafenib—Loss of consciousness—Docetaxel—melanoma	4.38e-05	0.000783	CcSEcCtD
Sorafenib—Cough—Docetaxel—melanoma	4.35e-05	0.000777	CcSEcCtD
Sorafenib—Diarrhoea—Carmustine—melanoma	4.33e-05	0.000774	CcSEcCtD
Sorafenib—Pruritus—Temozolomide—melanoma	4.33e-05	0.000773	CcSEcCtD
Sorafenib—Nausea—Bleomycin—melanoma	4.31e-05	0.00077	CcSEcCtD
Sorafenib—Hypertension—Docetaxel—melanoma	4.31e-05	0.000769	CcSEcCtD
Sorafenib—Vomiting—Dactinomycin—melanoma	4.3e-05	0.000768	CcSEcCtD
Sorafenib—Rash—Dactinomycin—melanoma	4.27e-05	0.000762	CcSEcCtD
Sorafenib—Myalgia—Docetaxel—melanoma	4.25e-05	0.000758	CcSEcCtD
Sorafenib—Arthralgia—Docetaxel—melanoma	4.25e-05	0.000758	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	4.22e-05	0.000753	CcSEcCtD
Sorafenib—Dizziness—Carmustine—melanoma	4.19e-05	0.000748	CcSEcCtD
Sorafenib—Diarrhoea—Temozolomide—melanoma	4.19e-05	0.000748	CcSEcCtD
Sorafenib—Dry mouth—Docetaxel—melanoma	4.15e-05	0.000742	CcSEcCtD
Sorafenib—Anaphylactic shock—Docetaxel—melanoma	4.07e-05	0.000727	CcSEcCtD
Sorafenib—Dizziness—Temozolomide—melanoma	4.05e-05	0.000723	CcSEcCtD
Sorafenib—Infection—Docetaxel—melanoma	4.04e-05	0.000722	CcSEcCtD
Sorafenib—Vomiting—Carmustine—melanoma	4.03e-05	0.000719	CcSEcCtD
Sorafenib—Nausea—Dactinomycin—melanoma	4.02e-05	0.000718	CcSEcCtD
Sorafenib—Shock—Docetaxel—melanoma	4e-05	0.000715	CcSEcCtD
Sorafenib—Rash—Carmustine—melanoma	3.99e-05	0.000713	CcSEcCtD
Sorafenib—Nervous system disorder—Docetaxel—melanoma	3.99e-05	0.000713	CcSEcCtD
Sorafenib—Dermatitis—Carmustine—melanoma	3.99e-05	0.000712	CcSEcCtD
Sorafenib—Thrombocytopenia—Docetaxel—melanoma	3.98e-05	0.000712	CcSEcCtD
Sorafenib—Headache—Carmustine—melanoma	3.97e-05	0.000709	CcSEcCtD
Sorafenib—Skin disorder—Docetaxel—melanoma	3.95e-05	0.000706	CcSEcCtD
Sorafenib—Vomiting—Temozolomide—melanoma	3.89e-05	0.000695	CcSEcCtD
Sorafenib—Anorexia—Docetaxel—melanoma	3.88e-05	0.000693	CcSEcCtD
Sorafenib—Rash—Temozolomide—melanoma	3.86e-05	0.000689	CcSEcCtD
Sorafenib—Dermatitis—Temozolomide—melanoma	3.85e-05	0.000689	CcSEcCtD
Sorafenib—Headache—Temozolomide—melanoma	3.83e-05	0.000685	CcSEcCtD
Sorafenib—Nausea—Carmustine—melanoma	3.76e-05	0.000672	CcSEcCtD
Sorafenib—ABCG2—lymph node—melanoma	3.76e-05	0.00125	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Docetaxel—melanoma	3.71e-05	0.000662	CcSEcCtD
Sorafenib—ABCB1—mammalian vulva—melanoma	3.7e-05	0.00123	CbGeAlD
Sorafenib—CYP2D6—head—melanoma	3.68e-05	0.00122	CbGeAlD
Sorafenib—Nausea—Temozolomide—melanoma	3.63e-05	0.000649	CcSEcCtD
Sorafenib—Dyspnoea—Docetaxel—melanoma	3.63e-05	0.000648	CcSEcCtD
Sorafenib—Dyspepsia—Docetaxel—melanoma	3.58e-05	0.00064	CcSEcCtD
Sorafenib—Decreased appetite—Docetaxel—melanoma	3.54e-05	0.000632	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Docetaxel—melanoma	3.51e-05	0.000628	CcSEcCtD
Sorafenib—Fatigue—Docetaxel—melanoma	3.51e-05	0.000627	CcSEcCtD
Sorafenib—Constipation—Docetaxel—melanoma	3.48e-05	0.000622	CcSEcCtD
Sorafenib—Pain—Docetaxel—melanoma	3.48e-05	0.000622	CcSEcCtD
Sorafenib—Gastrointestinal pain—Docetaxel—melanoma	3.33e-05	0.000594	CcSEcCtD
Sorafenib—Abdominal pain—Docetaxel—melanoma	3.22e-05	0.000575	CcSEcCtD
Sorafenib—Body temperature increased—Docetaxel—melanoma	3.22e-05	0.000575	CcSEcCtD
Sorafenib—Hypersensitivity—Docetaxel—melanoma	3e-05	0.000536	CcSEcCtD
Sorafenib—Asthenia—Docetaxel—melanoma	2.92e-05	0.000522	CcSEcCtD
Sorafenib—Pruritus—Docetaxel—melanoma	2.88e-05	0.000514	CcSEcCtD
Sorafenib—Diarrhoea—Docetaxel—melanoma	2.78e-05	0.000497	CcSEcCtD
Sorafenib—Dizziness—Docetaxel—melanoma	2.69e-05	0.000481	CcSEcCtD
Sorafenib—ABCB1—head—melanoma	2.65e-05	0.000878	CbGeAlD
Sorafenib—Vomiting—Docetaxel—melanoma	2.59e-05	0.000462	CcSEcCtD
Sorafenib—Rash—Docetaxel—melanoma	2.57e-05	0.000458	CcSEcCtD
Sorafenib—Dermatitis—Docetaxel—melanoma	2.56e-05	0.000458	CcSEcCtD
Sorafenib—Headache—Docetaxel—melanoma	2.55e-05	0.000455	CcSEcCtD
Sorafenib—Nausea—Docetaxel—melanoma	2.42e-05	0.000432	CcSEcCtD
Sorafenib—ABCB1—lymph node—melanoma	1.85e-05	0.000615	CbGeAlD
Sorafenib—KIT—Signaling Pathways—EGFR—melanoma	3.16e-07	3.65e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK3—melanoma	3.15e-07	3.65e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NFKB1—melanoma	3.15e-07	3.64e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—melanoma	3.14e-07	3.64e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK3—melanoma	3.14e-07	3.64e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—melanoma	3.14e-07	3.63e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—melanoma	3.13e-07	3.62e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—melanoma	3.12e-07	3.61e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP17A1—melanoma	3.1e-07	3.59e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—melanoma	3.09e-07	3.57e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—melanoma	3.08e-07	3.57e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTEN—melanoma	3.08e-07	3.57e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—melanoma	3.07e-07	3.55e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—melanoma	3.06e-07	3.54e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—melanoma	3.06e-07	3.54e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTEN—melanoma	3.05e-07	3.53e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PIK3CA—melanoma	3.05e-07	3.52e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PIK3CA—melanoma	3.04e-07	3.52e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—melanoma	3.04e-07	3.51e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MDM2—melanoma	3.03e-07	3.51e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CTNNB1—melanoma	3.03e-07	3.51e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.03e-07	3.5e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—melanoma	3.03e-07	3.5e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PRKCA—melanoma	3.03e-07	3.5e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PIK3CA—melanoma	3.01e-07	3.48e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ERCC2—melanoma	3e-07	3.47e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PRKCA—melanoma	3e-07	3.47e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CD—melanoma	3e-07	3.47e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK1—melanoma	3e-07	3.47e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—melanoma	3e-07	3.47e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—melanoma	2.99e-07	3.46e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK1—melanoma	2.99e-07	3.46e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—melanoma	2.99e-07	3.46e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB2—melanoma	2.99e-07	3.46e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.99e-07	3.46e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—melanoma	2.98e-07	3.45e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—melanoma	2.98e-07	3.45e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—melanoma	2.98e-07	3.45e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ERCC2—melanoma	2.98e-07	3.44e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—melanoma	2.98e-07	3.44e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—melanoma	2.97e-07	3.44e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—melanoma	2.96e-07	3.43e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—melanoma	2.96e-07	3.43e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1A—melanoma	2.96e-07	3.43e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—melanoma	2.96e-07	3.43e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NRAS—melanoma	2.96e-07	3.42e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—melanoma	2.96e-07	3.42e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—melanoma	2.95e-07	3.42e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTEN—melanoma	2.95e-07	3.42e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CB—melanoma	2.95e-07	3.41e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—melanoma	2.94e-07	3.4e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NFKB1—melanoma	2.94e-07	3.4e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CD—melanoma	2.93e-07	3.39e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNA11—melanoma	2.93e-07	3.39e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—melanoma	2.91e-07	3.37e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—melanoma	2.89e-07	3.35e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—melanoma	2.89e-07	3.34e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CG—melanoma	2.89e-07	3.34e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—melanoma	2.88e-07	3.33e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—FASN—melanoma	2.87e-07	3.32e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—melanoma	2.86e-07	3.3e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—melanoma	2.85e-07	3.3e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—melanoma	2.84e-07	3.28e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—melanoma	2.83e-07	3.28e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK3—melanoma	2.83e-07	3.28e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—melanoma	2.83e-07	3.27e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—melanoma	2.83e-07	3.27e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC5A5—melanoma	2.82e-07	3.26e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NRAS—melanoma	2.82e-07	3.26e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—melanoma	2.82e-07	3.26e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—melanoma	2.81e-07	3.25e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—melanoma	2.79e-07	3.22e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—melanoma	2.79e-07	3.22e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCB1—melanoma	2.79e-07	3.22e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1B—melanoma	2.77e-07	3.2e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—melanoma	2.75e-07	3.19e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—melanoma	2.75e-07	3.19e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—melanoma	2.74e-07	3.17e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—melanoma	2.74e-07	3.17e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—melanoma	2.74e-07	3.17e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—melanoma	2.73e-07	3.16e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNAQ—melanoma	2.72e-07	3.15e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CD44—melanoma	2.72e-07	3.15e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—melanoma	2.71e-07	3.14e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—melanoma	2.71e-07	3.14e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.7e-07	3.13e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK3—melanoma	2.7e-07	3.12e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—melanoma	2.7e-07	3.12e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK1—melanoma	2.7e-07	3.12e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—melanoma	2.69e-07	3.12e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—melanoma	2.69e-07	3.12e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—melanoma	2.67e-07	3.09e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—melanoma	2.67e-07	3.09e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—melanoma	2.65e-07	3.07e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—melanoma	2.65e-07	3.07e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—melanoma	2.64e-07	3.06e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—melanoma	2.64e-07	3.06e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NRAS—melanoma	2.64e-07	3.05e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—melanoma	2.64e-07	3.05e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—melanoma	2.63e-07	3.05e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—melanoma	2.63e-07	3.04e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CTNNB1—melanoma	2.62e-07	3.03e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CB—melanoma	2.61e-07	3.02e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1B1—melanoma	2.61e-07	3.02e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—melanoma	2.6e-07	3.01e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—melanoma	2.6e-07	3e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—melanoma	2.59e-07	3e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CG—melanoma	2.58e-07	2.98e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK1—melanoma	2.57e-07	2.97e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—melanoma	2.57e-07	2.97e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—melanoma	2.57e-07	2.97e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PRKCA—melanoma	2.56e-07	2.97e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—melanoma	2.56e-07	2.96e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—melanoma	2.56e-07	2.96e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1A—melanoma	2.56e-07	2.96e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CB—melanoma	2.56e-07	2.96e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTEN—melanoma	2.55e-07	2.95e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—melanoma	2.55e-07	2.94e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ERCC2—melanoma	2.54e-07	2.94e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CD—melanoma	2.54e-07	2.94e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NFKB1—melanoma	2.54e-07	2.94e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—melanoma	2.54e-07	2.93e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—melanoma	2.54e-07	2.93e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—melanoma	2.53e-07	2.93e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK3—melanoma	2.52e-07	2.92e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—melanoma	2.52e-07	2.91e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CG—melanoma	2.52e-07	2.91e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—melanoma	2.51e-07	2.9e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—melanoma	2.51e-07	2.9e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—melanoma	2.49e-07	2.88e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—melanoma	2.49e-07	2.88e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—melanoma	2.48e-07	2.87e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.47e-07	2.85e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—melanoma	2.46e-07	2.85e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—melanoma	2.46e-07	2.84e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—melanoma	2.43e-07	2.81e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—melanoma	2.43e-07	2.81e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—melanoma	2.43e-07	2.81e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—melanoma	2.43e-07	2.81e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—melanoma	2.43e-07	2.81e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—melanoma	2.41e-07	2.79e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK1—melanoma	2.4e-07	2.78e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—melanoma	2.4e-07	2.78e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—melanoma	2.4e-07	2.78e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CG—melanoma	2.37e-07	2.74e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CG—melanoma	2.35e-07	2.72e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—melanoma	2.34e-07	2.71e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—melanoma	2.3e-07	2.67e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—melanoma	2.3e-07	2.66e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—melanoma	2.3e-07	2.66e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—melanoma	2.29e-07	2.65e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—melanoma	2.28e-07	2.64e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRAS—melanoma	2.28e-07	2.63e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—melanoma	2.27e-07	2.62e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—melanoma	2.27e-07	2.62e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CD—melanoma	2.27e-07	2.62e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—melanoma	2.26e-07	2.62e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTEN—melanoma	2.26e-07	2.61e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—melanoma	2.24e-07	2.59e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—melanoma	2.24e-07	2.59e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—melanoma	2.24e-07	2.59e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—melanoma	2.23e-07	2.58e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CB—melanoma	2.21e-07	2.56e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CD—melanoma	2.21e-07	2.56e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTEN—melanoma	2.21e-07	2.55e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—melanoma	2.19e-07	2.54e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—melanoma	2.18e-07	2.53e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK3—melanoma	2.18e-07	2.52e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—melanoma	2.17e-07	2.52e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—melanoma	2.16e-07	2.5e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—melanoma	2.16e-07	2.5e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—melanoma	2.16e-07	2.49e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCB1—melanoma	2.15e-07	2.49e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—melanoma	2.13e-07	2.46e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—melanoma	2.12e-07	2.45e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—melanoma	2.12e-07	2.45e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.11e-07	2.44e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—melanoma	2.09e-07	2.42e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—melanoma	2.09e-07	2.42e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CD—melanoma	2.08e-07	2.41e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—melanoma	2.08e-07	2.41e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK1—melanoma	2.07e-07	2.4e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—melanoma	2.07e-07	2.4e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—melanoma	2.07e-07	2.4e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CD—melanoma	2.07e-07	2.39e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—melanoma	2.06e-07	2.39e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—melanoma	2.06e-07	2.38e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—melanoma	2.04e-07	2.36e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—melanoma	2.02e-07	2.33e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CG—melanoma	2.01e-07	2.32e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PRKCA—melanoma	1.98e-07	2.29e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CB—melanoma	1.98e-07	2.29e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—melanoma	1.97e-07	2.28e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ERCC2—melanoma	1.96e-07	2.27e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—melanoma	1.96e-07	2.27e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—melanoma	1.96e-07	2.26e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—melanoma	1.94e-07	2.24e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—melanoma	1.93e-07	2.23e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CB—melanoma	1.93e-07	2.23e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTEN—melanoma	1.91e-07	2.21e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—melanoma	1.91e-07	2.21e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—melanoma	1.91e-07	2.21e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—melanoma	1.85e-07	2.13e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—melanoma	1.82e-07	2.11e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CB—melanoma	1.82e-07	2.1e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CB—melanoma	1.8e-07	2.08e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—melanoma	1.8e-07	2.08e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—melanoma	1.8e-07	2.08e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—melanoma	1.79e-07	2.06e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—melanoma	1.78e-07	2.05e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CD—melanoma	1.77e-07	2.04e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—melanoma	1.76e-07	2.04e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—melanoma	1.74e-07	2.02e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—melanoma	1.74e-07	2.01e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTEN—melanoma	1.71e-07	1.97e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—melanoma	1.7e-07	1.97e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTEN—melanoma	1.67e-07	1.93e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—melanoma	1.66e-07	1.93e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—melanoma	1.59e-07	1.84e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—melanoma	1.59e-07	1.84e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTEN—melanoma	1.57e-07	1.82e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—melanoma	1.56e-07	1.8e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTEN—melanoma	1.56e-07	1.8e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CG—melanoma	1.55e-07	1.79e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CB—melanoma	1.54e-07	1.78e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—melanoma	1.53e-07	1.76e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—melanoma	1.5e-07	1.73e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—melanoma	1.47e-07	1.7e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CD—melanoma	1.36e-07	1.58e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—melanoma	1.35e-07	1.56e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—melanoma	1.35e-07	1.56e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTEN—melanoma	1.33e-07	1.54e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—melanoma	1.3e-07	1.51e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—melanoma	1.27e-07	1.47e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—melanoma	1.2e-07	1.39e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CB—melanoma	1.19e-07	1.37e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—melanoma	1.18e-07	1.36e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—melanoma	1.18e-07	1.36e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—melanoma	1.11e-07	1.28e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—melanoma	1.1e-07	1.28e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—melanoma	1.1e-07	1.27e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTEN—melanoma	1.03e-07	1.19e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—melanoma	9.84e-08	1.14e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—melanoma	9.6e-08	1.11e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—melanoma	9.38e-08	1.09e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—melanoma	9.05e-08	1.05e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—melanoma	8.97e-08	1.04e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—melanoma	7.67e-08	8.87e-07	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—melanoma	7.24e-08	8.38e-07	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—melanoma	5.92e-08	6.84e-07	CbGpPWpGaD
